NFL BIOSCIENCES S.A.NN

NFL BIOSCIENCES S.A.

1.740EURD
−0.020−1.14%
At close at Feb 24, 16:23 GMT
EUR
No trades
See on Supercharts

ALNFL fundamentals

Key facts

Market capitalization‪17.08 M‬EUR
Basic EPS (TTM)−0.28EUR
Founded2006
CEOBruno Lafont
About

NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. Its pipeline includes NFL-101 tobacco extract; NFL-201 cannabis and tobacco extract; and NFL-301 botanical extract. The company was founded by Bruno Lafont and Jean-Pierre Nicolas in September 2006 and is headquartered in Castelnau-le-Lez, France.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪17.08 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Valuation ratios
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24

Growth and Profitability

Company’s recent performance and margins

Performance
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24
‪‪−2.40 M‬‬
‪‪−1.80 M‬‬
‪‪−1.20 M‬‬
‪‪−600.00 K‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−1.00 M‬‬
‪‪−750.00 K‬‬
‪‪−500.00 K‬‬
‪‪−250.00 K‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−800.00 K‬‬
‪‪−600.00 K‬‬
‪‪−400.00 K‬‬
‪‪−200.00 K‬‬
‪0.00‬

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H1 '24
‪0.00‬
Actual
Earnings
Next:Mar 31, 2025
2021
2022
2023
2024
‪−0.60‬
‪−0.45‬
‪−0.30‬
‪−0.15‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

ALNFL does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24
‪0.00‬
‪‪900.00 K‬‬
‪‪1.80 M‬‬
‪‪2.70 M‬‬
‪‪3.60 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪1.20 M‬‬
‪‪2.40 M‬‬
‪‪3.60 M‬‬
‪‪4.80 M‬‬
Assets
Liabilities